Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accumulated Expenses: 2024

Historic Accumulated Expenses for Kura Oncology (KURA) over the last 1 years, with Dec 2024 value amounting to $17.5 million.

  • Kura Oncology's Accumulated Expenses rose 16.93% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 16.93%. This contributed to the annual value of $17.5 million for FY2024, which is N/A change from last year.
  • As of FY2024, Kura Oncology's Accumulated Expenses stood at $17.5 million.
  • Kura Oncology's 5-year Accumulated Expenses high stood at $17.5 million for FY2024, and its period low was $17.5 million during FY2024.
  • Over the past 1 years, Kura Oncology's median Accumulated Expenses value was $17.5 million (recorded in 2024), while the average stood at $17.5 million.